Abstract
In this study the antimicrotubular agents taxol, taxotere, and vinblastine were compared for their ability to inhibit the clonal growth of human bladder tumor cell lines using a soft-agar clonogenic assay. The stability of taxol and taxotere was evaluated by high-performance liquid chromatography over a range of pH in human urine. Both taxol and taxotere were shown to maximally inhibit the clonal growth of human bladder cell lines within 1 h of drug incubation. The most active agent in the panel of tumor lines was taxotere, with 6 of 12 lines being sensitive to the agent at 0.01 μM and all cell lines being sensitive at 0.1 μM. Taxol was active in 1 of 12 lines at 0.01 μM and in 11 of 12 at 0.1 μM. Only 2 of 12 cell lines were sensitive to vinblastine over the 0.01- to 0.1-μM dose range. Taxol and taxotere were found to be stable in human urine for 4 h over a pH range of 5–7. At least 85% of both drugs were present during this period of drug incubation. Our findings suggest that both taxol and taxotere may be clinically useful agents for systemic and intravesical use in bladder cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alberts DS, Garcia D, Fanta P, Liu R, Roe D, Salmon SE (1992) Comparative cytotoxicities of taxol and taxotere in vitro against fresh human ovarian cancers. Proc Am Soc Clin Oncol 11: 226
Bissery M-C, Guenard D, Gueritte-Voegelein F, Lavelle F (1991) Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845–4852
Blumenreich MS, Yagoda A, Natale RB, Watson RC (1982) Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 50: 435–438
Chang A, Kim K, Glick J, Anerson T, Karp K, Hohnson D (1992) Phase II study of taxol in patients with stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol 11: 293
Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff M-T, Mangatal L, Potier P (1991) Relationships between the structure of taxol analogs and their antimitotic activity. J Med Chem 34: 992–998
Hamburger A, Salmon SE (1977) Primary bioassay of human myeloma stem cells. J Clin Invest 60: 846–854
Hepburn PJ, Masters JRW (1983) The biological characteristics of continuous cell lines derived from human bladder. In: Bryan GT, Cohen SM (eds) The pathology of bladder cancer, vol 2. CRC Press. Boca Raton, Florida, p 213–227
Holmes RA, Walters RS, Theriault RL, Forman AD, Newton LK (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797–1805
Longnecker SM, Donehower RC, Cates AE, Chen T-L, Brundrett RB, Growchow LB, Ettinger DS, Colvin M (1987) High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71: 53–59
Manfredi JJ, Horwitz SB (1984) Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 25: 83–125
Masters JRW, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, Parker M, Hill BT, Riddle PR, Franks LM (1986) Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res 46: 360–363
McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273–279
National Cancer Institute (1983) Clinical brochure: Taxol(NSC 125973). NCI, Division of Cancer Treatment, Bethesda, Maryland, pp 6–12
Niell HB, Webster KC, Smith EE (1985) Anticancer drug activity in human bladder tumor cell lines. Cancer 56: 1039–1044
Raghavan D, Shipley W, Garnick M, Russell P, Richie JP (1990) Biology and management of bladder cancer. New Engl J Med 322: 1129–1138
Ringel I, Horwitz SB (1991) Effect of alkaline pH on taxol-microtubule interactions. J Pharmacol Exp Ther 259: 855–860
Ringel I, Horwitz SB (1991) Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288–291
Ringel L, Horwitz SB (1987) Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. J Pharmacol Exp Ther 242: 692–698
Rowinsky EK, Donehower RC, Jones RJ, Tucker RW (1988) Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48: 4093–4100
Sarosy G, Kohn E, Link C, Adamo D, Davis P, Ognibene R, Goildspiel B, Christian M, Reed E (1992) Taxol dose intensification in patients with recurrent ovarian cancer. Proc Am Soc Clin Res 11: 226
Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol Nature 277: 665–667
Schiff PM, Horwitz SB (1980) Taxol stabilized microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561
Soloway MS (1987) Selecting initial therapy for bladder cancer. Cancer 60: 503–513
Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47: 2486–2493
Author information
Authors and Affiliations
Additional information
This work was supported in part by the Veterans Administration Research Service
Rights and permissions
About this article
Cite this article
Rangel, C., Niell, H., Miller, A. et al. Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother. Pharmacol. 33, 460–464 (1994). https://doi.org/10.1007/BF00686501
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686501